ArticleThe Lancet. Haematology2021

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.

Mehdi Hamadani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.